OakChart

Neurocrine Biosciences Inc

NBIXHealthcare·Drug Manufacturers - Specialty & Generic·USA·Large·NASD·Nov 11 • 3:59 PM ET

174.41+5.27 (3.12%)
2026-11-12 06:44 CET
Market cap
17,653.61 USD m
Revenue, TTM
3,701.70 USD m
Net income, TTM
702.50 USD m
Free cash flow, TTM
973.10 USD m
EPS diluted, TTM
6.74
P/E
25.86
Compare

Price

NBIX against its 20, 50 and 200-day averages
2050200beatmiss
140.00160.00180.002.3M4.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NBIXclose 174.4120-day 151.0950-day 148.17200-day 148.56174.4152w high

6.3% under the 52-week high of 186.12 on 30 Jul 2026. 52-week low 122.14 on 12 Feb 2026. Last 15 sessions, 24.0% high to low

Volume 0.86× normal · the line is the 50-bar volume average

Profile

NBIX
52-week range, 82% of the way up
122.14186.12

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

IndexRUI
Employees2000
IPOMay 23, 1996
Beta0.31
ATR, 14d5.45
Rel volume0.86
Short float5.90%
Insider own1.21%
Inst own103.74%

Snapshot

6 groups

Valuation

IndexRUI
Market Cap17.65B
Enterprise Value17.31B
Income702.50M
Sales3.70B
Book/sh38.29
Cash/sh7.29
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees2000
IPOMay 23, 1996

Ratios

P/E25.86
Forward P/E17.88
PEG0.48
P/S4.77
P/B4.56
P/C23.92
P/FCF18.14
EV/EBITDA17.42
EV/Sales4.68
Quick Ratio1.97
Current Ratio2.04
Debt/Eq0.10
LT Debt/Eq0.10
Option/ShortYes / Yes

Earnings

EPS (ttm)6.74
EPS next Y9.75
EPS next Q2.06
EPS this Y56.91%
EPS next Y33.09%
EPS next 5Y36.95%
EPS past 3/5Y44.05% 2.31%
Sales past 3/5Y24.32% 22.29%
EPS Y/Y TTM61.95%
Sales Y/Y TTM37.98%
EPS Q/Q-3.96%
Sales Q/Q41.24%
EarningsNov 02 AMC
EPS/Sales Surpr.2.62% 7.64%

Ownership

Insider Own1.21%
Insider Trans-25.34%
Inst Own103.74%
Inst Trans-1.36%
ROA14.20%
ROE20.41%
ROIC16.45%
Gross Margin96.42%
Oper. Margin24.58%
Profit Margin18.98%
SMA2015.43%
SMA5017.71%
SMA20017.40%
Trades-

Technical

Shs Outstand101.30M
Shs Float100.00M
Short Float5.90%
Short Ratio4.45
Short Interest5.90M
52W High186.12 -6.29%
52W Low122.14 42.80%
Volatility3.91% 2.96%
ATR (14)5.45
RSI (14)75.77
Beta0.31
Rel Volume0.86
Avg Volume1.33M
Volume1,144,739

Performance

Perf Week5.03%
Perf Month29.07%
Perf Quarter15.64%
Perf Half Y8.11%
Perf YTD22.97%
Perf Year18.41%
Perf 3Y62.74%
Perf 5Y95.46%
Perf 10Y231.70%
Recom1.38
Target Price209.05
Prev Close169.14
Price174.41
Change %3.12%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 06, 2026ResumedGGuggenheimBuy$207+18.7%
Jun 02, 2026ResumedGGoldmanBuy$213+22.1%
May 22, 2026InitiatedBBernsteinOutperform$221+26.7%
Feb 24, 2026InitiatedWWolfe ResearchOutperform$160-8.3%
Jan 08, 2026DowngradeMMorgan StanleyOverweight → Equal-Weight$175+0.3%
Oct 21, 2025InitiatedCCitigroupBuy$175+0.3%
Jul 21, 2025InitiatedTTruistBuy$163-6.5%
Jul 10, 2025InitiatedGGoldmanBuy$182+4.4%
Apr 15, 2025UpgradeNNeedhamHold → Buy$138-20.9%
Apr 14, 2025UpgradeRRBC Capital MktsSector Perform → Outperform$137-21.4%

Peers

Mkt cap
TickerCompanyMkt cap
TEVATeva- Pharmaceutical Industries Ltd50.45B
ALKSAlkermes plc8.05B
AXSMAxsome Therapeutics Inc7.85B
JAZZJazz Pharmaceuticals plc15.93B
SUPNSupernus Inc6.12B
ACADAcadia Pharmaceuticals Inc3.17B
BIIBBiogen Inc37.46B
BMYBristol-Myers Squibb Co128.59B
HRMYHarmony Biosciences Holdings Inc2.01B
EXELExelixis Inc17.25B

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
SANJAY KESWANIFormer AffiliateNov 10 '26Proposed Sale167.3753,6148,973,488Nov 10 04:47 PM
MORROW GEORGE JDirectorNov 02 '26Option Exercise53.647,500402,30017,886Nov 03 06:52 PM
MORROW GEORGE JDirectorNov 03 '26Option Exercise53.647,200386,20817,586Nov 03 06:52 PM
MORROW GEORGE JDirectorOct 30 '26Option Exercise53.6430016,09210,686Nov 03 06:52 PM
MORROW GEORGE JDirectorNov 03 '26Sale166.377,2001,197,85210,386Nov 03 06:52 PM
MORROW GEORGE JDirectorNov 02 '26Sale145.797,5001,093,43010,386Nov 03 06:52 PM
MORROW GEORGE JDirectorOct 30 '26Sale149.0030044,70010,386Nov 03 06:52 PM
Gano KyleChief Executive OfficerNov 01 '26Option Exercise0.006140155,342Nov 03 05:59 PM
GEORGE MORROWDirectorNov 02 '26Proposed Sale146.1014,7002,147,670Nov 02 04:38 PM
GEORGE MORROWDirectorOct 30 '26Proposed Sale146.3830043,914Oct 30 04:20 PM
Boyer David W.Chief Corp. Affairs OfficerSep 14 '26Sale157.45826130,0518,722Sep 15 05:03 PM
ABERNETHY MATTChief Financial OfficerSep 14 '26Sale157.202,311363,28542,808Sep 15 05:02 PM
MATTHEW C ABERNETHYOfficerSep 14 '26Proposed Sale156.222,311361,024Sep 14 04:49 PM
DAVID WARREN BOYEROfficerSep 14 '26Proposed Sale156.224,714736,421Sep 14 04:39 PM

Held by

AUM
TickerCompanyAUM
IJHiShares Core S&P Mid-Cap ETFAUM: 124.48B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
VFLOVictoryShares Free Cash Flow ETFAUM: 12.50B
MDYState Street SPDR S&P MIDCAP 400 ETF TrustAUM: 26.22B
FBTFirst Trust NYSE Arca Biotechnology Index FundAUM: 3.03B

News

latest 14 of 200
  • Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference (PR Newswire)
  • Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA (valbenazine) Capsules (PR Newswire)
  • Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress (PR Newswire) +13.42%
  • This Biopharma Stock Hit a 6-Year High-and It Can Keep Climbing (Barrons.com)
  • Neurocrine: Q3 Earnings Snapshot (Associated Press)
  • Neurocrine Crushes Estimates And Raises INGREZZA Again, But VYKAT XR Doubts And A Softer Q4 Cloud The Record Quarter (Earnings Whispers)
  • Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results (PR Newswire)
  • Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia (PR Newswire)
  • Neurocrine's 23% Slide Puts Ingrezza Raise And Crenessity Ramp Under The Microscope (Earnings Whispers)
  • Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia (PR Newswire)
  • Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome (PR Newswire)
  • Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease (PR Newswire)
  • Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia (PR Newswire)
  • Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-021.9601.9101.9601,1231,04322
2026Q22026-07-301.3901.6501.386959891.1621
2026Q12026-05-051.9101.2161.914814.5768.2521
2025Q42026-02-111.4801.8041.482805.5790.521
2025Q32025-10-282.0401.5942.044794.9746.8519
2025Q22025-07-301.0600.9651.064687.5653.8820
2025Q12025-05-050.0800.5350.077572.6559.6320
2024Q42025-02-061.0001.6061.002627.7629.4618
2024Q32024-10-301.2401.5051.245622.1600.6422
2024Q22024-08-010.6301.1280.626590.2545.9821
2024Q12024-05-010.4201.0980.419515.3512.420
2023Q42024-02-071.4401.2121.444515.2518.5223
2023Q32023-10-310.8201.0390.822498.8479.0923
2023Q22023-08-010.9500.8150.953452.7447.3421
2023Q12023-05-03-0.7900.617-0.789420.4410.6613
2022Q42023-02-060.8801.1200.883412408.8720

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY0.3900.8330.387788.1776.32
2020FY4.1601.1984.1651,0461,056
2021FY0.9201.7830.9151,1341,137
2022FY1.5602.2171.5621,4891,484
2023FY2.4702.5592.4721,8871,889
2024FY3.2903.9533.2912,3552,356
2025FY4.6705.0374.6702,8612,845
2026FY-7.328--3,987
2027FY-9.752--4,566
2028FY-11.995--5,038
2029FY-12.512--5,143
2030FY-13.572--5,491

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-09241341,0931,0551,280
2026Q4S2026-11-08241241,0921,0551,280
2026Q4S2026-11-03251241,0921,0551,280
2026Q4S2026-11-0225341,0821,0411,196
2026Q4S2026-10-2925341,0821,0411,196
2026Q4S2026-10-2825331,0841,0411,196
2026Q4S2026-10-2725331,0841,0411,196
2026Q4S2026-10-2524331,0841,0411,196
2026Q4S2026-10-1824341,0841,0411,196
2026Q4S2026-10-1524441,0841,0411,196
2026Q4S2026-10-1424341,0841,0411,196
2026Q4S2026-10-12241461,0841,0411,196
2026Q4S2026-10-09241461,0841,0411,196
2026Q4S2026-10-07241551,0851,0411,196

Estimate history

EPS, annual-1.620.2210.3874.1650.9151.5622.4723.2914.6696.7448
Period201720182019202020212022202320242025TTM
EPS, quarterly1.2451.0020.0771.0642.0441.4821.9141.3861.963
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual161.626451.24788.0871045.91133.51488.71887.12355.32860.53701.7
Period201720182019202020212022202320242025TTM
Sales, quarterly622.1627.7572.6687.5794.9805.5814.59591122.7
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual88.79490.79792.27293.594.996.598.799.4100.1101.3
Period201720182019202020212022202320242025MRQ
Shares, quarterly101.299.4999999.7100.1100.6101.6101.3
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue3,701.702,860.502,355.301,887.101,488.701,133.501,045.90788.09451.24
Cost of Goods Sold Incl. D&A132.6052.1057.5057.5038.3025.2018.7014.884.89
Gross Profit3,569.102,808.402,297.801,829.601,450.401,108.301,027.20773.21446.35
Selling, General and Administrative Excl. Other2,659.202,171.901,700.801,434.801,199.70900.50699.70546.65409.46
Research and Development1,232.901,015.70707.60547.20448.70317.20266.40192.59160.52
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income909.90636.50597.00394.80250.70207.80327.50226.5636.90
Interest Expense3.200.00126.604.607.1025.8032.8031.9630.53
Unusual Expense74.5021.4075.40115.5040.9084.40200.60167.26-
Net Income Before Taxes932.10705.40486.00332.10213.90101.40106.7046.5421.84
Income Taxes229.60226.80144.7082.4059.4011.80-300.609.530.73
Consolidated Net Income702.50478.60341.30249.70154.5089.60407.3037.0121.11
Net Income From Continuing Operations702.50478.60341.30249.70154.5089.60407.3037.0121.11
Net Income702.50478.60341.30249.70154.5089.60407.3037.0121.11
EPS (Recurring)7.174.823.803.271.851.525.601.610.22
EPS (Basic, Before Extraordinaries)6.974.813.402.561.610.954.370.400.23
EPS (Diluted)6.744.673.292.471.560.924.160.390.22
EBITDA993.50666.60624.10416.10266.30218.70336.10234.0140.92
Non-Operating Income (Expense)99.9090.3091.0057.4011.203.8012.6019.2115.48
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense185.73172.14154.44153.502.5097.9773.0054.9445.87
Price To Earnings Ratio25.8625.8636.5770.49205.7293.2723.05325.83395.40
Price To Sales Ratio4.035.086.017.057.937.368.9613.0615.10
Gross Margin96.4298.1897.5696.9597.4397.7898.2198.1198.92
Operating Margin24.5822.2525.3520.9216.8418.3331.3128.758.18
Net Margin18.9816.7314.4913.2310.387.9038.944.704.68
Shares Outstanding101.30100.1099.4098.7096.5094.9093.5092.2790.80
Market Capitalization17,653.6117,653.6113,820.2212,945.6711,482.298,079.808,955.199,899.186,475.60

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1,122.70959.00814.50805.50794.90687.50572.60627.70
Cost of Goods Sold Incl. D&A61.6039.6013.8017.6014.0011.309.2015.50
Gross Profit1,061.10919.40800.70787.90780.90676.20563.40612.20
Selling, General and Administrative Excl. Other718.10766.40614.70560.00541.60530.60539.70467.20
Research and Development351.80326.70296.20258.20250.00244.30263.20179.40
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income343.00153.00186.00227.90239.30145.6023.70145.00
Interest Expense0.302.900.000.000.00---
Unusual Expense64.000.30-4.1014.30-30.306.7030.704.90
Net Income Before Taxes283.70162.20246.80239.40291.80159.5014.70162.60
Income Taxes77.2017.8048.9085.7082.3052.006.8059.50
Consolidated Net Income206.50144.40197.90153.70209.50107.507.90103.10
Net Income From Continuing Operations206.50144.40197.90153.70209.50107.507.90103.10
Net Income206.50144.40197.90153.70209.50107.507.90103.10
EPS (Recurring)2.391.391.891.581.841.110.291.04
EPS (Basic, Before Extraordinaries)2.031.431.971.542.111.090.081.03
EPS (Diluted)1.961.391.911.482.041.060.081.00
EBITDA387.00177.80193.30235.40247.00152.9031.30152.10
Non-Operating Income (Expense)5.0012.4056.7025.8022.2020.6021.7022.50
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense42.9051.3545.1946.2942.4241.7141.7152.46
Price To Earnings Ratio25.8625.9128.2233.8741.4442.6233.6136.57
Price To Sales Ratio4.035.214.395.145.365.064.705.96
Gross Margin94.5195.8798.3197.8298.2498.3698.3997.53
Operating Margin30.5515.9522.8428.2930.1021.184.1423.10
Net Margin18.3915.0624.3019.0826.3615.641.3816.43
Shares Outstanding101.30101.60100.60100.1099.7099.0099.0099.40
Market Capitalization17,653.6116,946.1913,221.8214,141.2613,923.1012,439.0111,027.2113,820.22

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1,480.401,076.101,031.60989.30711.30801.00670.52650.91515.93
Short Term Receivables686.80479.10439.30350.00185.50157.10126.5856.2431.13
Inventories69.0057.4038.3035.1030.5028.0017.2910.860.00
Other Current Assets286.50112.1097.8079.1045.5030.1016.6519.767.86
Total Current Assets2,522.701,724.701,607.001,453.50972.801,016.20831.03737.78554.92
Net Property, Plant & Equipment545.20592.00347.30145.60155.80127.40116.2833.8710.81
Total Investments and Advances1,191.80872.30857.40401.50624.40268.50358.73221.50251.86
Intangible Assets-38.5031.9033.80--0.000.000.00
Deferred Tax Assets442.10614.00441.20338.70315.10319.40---
Other Assets51.505.5045.2028.404.403.200.000.000.00
Total Assets4,753.303,847.003,330.002,401.502,072.501,734.701,306.04993.15817.59
Short Term Debt Incl. Current Port. of LT Debt56.0040.60202.10186.8016.5010.30417.090.000.00
Accounts Payable104.90110.00108.9076.3051.5039.4046.2113.805.65
Income Tax Payable68.00-24.40------
Other Current Liabilities514.50357.10319.40274.60177.80136.80101.9874.4348.78
Total Current Liabilities743.40507.70654.80537.70245.80186.50565.2988.2354.43
Long Term Debt415.30455.10258.3093.50440.40412.3086.76388.50369.62
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities121.80128.3078.6032.80-----
Other Liabilities219.70166.20106.3029.7012.309.7017.0735.6621.41
Total Liabilities1,500.201,257.301,098.00693.70698.50608.50669.12512.39445.45
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity3,253.102,589.702,232.001,707.801,374.001,126.20636.92480.76372.14
Total Shareholders Equity3,253.102,589.702,232.001,707.801,374.001,126.20636.92480.76372.14
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity3,253.102,589.702,232.001,707.801,374.001,126.20636.92480.76372.14
Total Liabilities & Stockholders Equity4,753.303,847.003,330.002,401.502,072.501,734.701,306.04993.15817.59
Book Value Per Share32.5026.0522.6117.7014.4812.046.905.294.19
Tangible Book Value Per Share32.5025.6722.2917.3514.4812.046.905.294.19
Full-Time Employees2,0001,8001,4001,200900845700585400
Price to Book Ratio4.565.086.467.435.887.9615.5713.4919.75
Return on Assets11.139.518.716.914.7126.793.222.33-24.10
Return on Equity16.3814.1612.6810.037.1746.206.624.95-41.50
Return on Invested Capital13.0511.2110.038.584.9426.475.112.43-19.22
Quick Ratio3.303.282.402.643.835.301.448.2410.20
Current Ratio3.393.402.452.703.965.451.478.3610.20

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income702.50478.60341.30249.70154.5089.60407.3037.0121.11
Depreciation83.6030.1027.1021.3015.6010.908.607.454.02
Other Funds (Non Cash)184.70237.40369.30147.40217.60135.00161.20107.3577.99
Funds from Operations943.20911.50614.60361.70406.80239.80266.40151.81103.12
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital56.00-128.80-19.2028.20-67.4016.70-37.900.24-1.76
Cash from Operating Activities999.20782.70595.40389.90339.40256.50228.50152.05101.36
Capital Expenditures-26.10-34.00-38.20-28.30-16.50-23.40-10.90-14.75-24.81
Net Assets From Acquisitions-2,358.500.000.000.00-42.700.000.000.00-
Sale of Fixed Assets and Businesses63.200.000.000.000.000.000.000.010.03
Purchase or Sale of Investments1,615.80-230.40-88.60-438.80-117.90-106.8015.00-196.33-218.14
Purchase of Investments-1,184.40-1,319.80-1,056.10-1,411.20-628.90-804.70-735.50-866.02-545.96
Sale Or Maturity of Investments2,800.201,089.40967.50972.40511.00697.90750.50669.69327.82
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-705.60-264.40-126.80-467.10-177.10-130.204.10-211.07-242.91
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock12.90-38.30-177.9065.3044.7027.5029.1027.3129.53
Repurchase of Common Pref Stock-158.10-167.70-300.000.000.000.000.000.000.00
Sale of Common Pref Stock171.00129.40122.1065.3044.7027.5029.1027.3129.53
Proceedsfrom Stock Options0.000.000.000.000.0027.5029.1027.3129.53
Issuance or Reduction of Debt, Net-6.700.00-308.800.00-279.00-0.10-186.900.000.00
Change in Long Term Debt-6.700.00-308.800.00-279.00-0.10-186.900.000.00
Issuance of Long Term Debt593.300.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-600.000.00-308.800.00-279.00-0.10-186.900.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities6.20-38.30-486.7065.30-234.3027.40-157.8027.3129.53
Exchange Rate Effect-0.000.000.30-1.30----
Net Change in Cash299.80480.00-18.10-11.60-73.30153.7074.80-31.71-112.02
Free Cash Flow973.10748.70557.20361.60322.90233.10217.60137.3176.55
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow15.3319.4225.4036.8036.5835.7743.0874.9488.98
Deferred Taxes & Investment Tax Credit-165.40-123.10-56.7019.104.30-310.700.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments737.90389.801,316.201,480.401,114.80975.60
Short Term Receivables957.30887.00768.10686.80728.00595.70
Inventories66.10104.2064.5069.0069.3056.90
Other Current Assets246.90256.50287.30286.50246.30120.70
Total Current Assets2,008.201,637.502,436.102,522.702,158.401,748.90
Net Property, Plant & Equipment529.40538.50538.00545.20566.20584.00
Total Investments and Advances153.30245.701,485.101,191.801,124.60969.30
Intangible Assets2,691.602,726.60--35.7037.20
Deferred Tax Assets11.808.90381.40442.10368.50536.80
Other Assets233.10201.9065.6051.5012.3013.60
Total Assets5,627.405,359.104,906.204,753.304,265.703,889.80
Short Term Debt Incl. Current Port. of LT Debt0.000.000.0056.0051.3050.70
Accounts Payable150.50142.00120.00104.90119.90104.60
Income Tax Payable150.10114.60186.4068.00-25.70
Other Current Liabilities684.00617.90525.30514.50466.80365.30
Total Current Liabilities984.60874.50831.70743.40638.00546.30
Long Term Debt392.30401.80406.20415.30428.40439.10
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities105.0091.50-121.80--
Other Liabilities266.80297.70260.90219.70195.70210.10
Total Liabilities1,748.701,665.501,498.801,500.201,262.101,195.50
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity3,878.703,693.603,407.403,253.103,003.602,694.30
Total Shareholders Equity3,878.703,693.603,407.403,253.103,003.602,694.30
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity3,878.703,693.603,407.403,253.103,003.602,694.30
Total Liabilities & Stockholders Equity5,627.405,359.104,906.204,753.304,265.703,889.80
Book Value Per Share38.2936.3533.8732.5030.1327.22
Tangible Book Value Per Share11.729.5233.8732.5029.7726.84
Full-Time Employees---2,000--
Price to Book Ratio4.564.984.054.715.164.91
Return on Assets14.2015.2615.5611.1310.979.68
Return on Equity20.4122.0922.5016.3814.9613.39
Return on Invested Capital4.833.535.194.196.103.43
Quick Ratio1.971.752.853.303.273.10
Current Ratio2.041.872.933.393.383.20

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income206.50144.40197.90153.70209.50107.50
Depreciation44.0024.807.307.507.707.30
Other Funds (Non Cash)106.0014.204.7059.8027.2063.70
Funds from Operations367.10158.10148.80269.20412.70141.10
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital19.90-80.10-3.00119.20-185.20-39.10
Cash from Operating Activities387.0078.00145.80388.40227.50102.00
Capital Expenditures-11.60-7.80-9.102.40-13.20-12.50
Net Assets From Acquisitions0.00-2,358.500.000.000.000.00
Sale of Fixed Assets and Businesses0.000.0063.200.000.000.00
Purchase or Sale of Investments0.502,230.90-560.30-55.30-183.50-16.50
Purchase of Investments-4.50-37.40-819.50-323.00-408.50-315.10
Sale Or Maturity of Investments5.002,268.30259.20267.70225.00298.60
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-11.10-135.40-506.20-52.90-196.70-29.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-66.80128.50-86.1037.3045.60-3.30
Repurchase of Common Pref Stock-92.1043.70-109.700.000.00-17.70
Sale of Common Pref Stock25.3084.8023.6037.3045.6014.40
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.00-6.700.000.000.000.00
Change in Long Term Debt0.00-6.700.000.000.000.00
Issuance of Long Term Debt0.00593.300.000.000.000.00
Reduction of Long Term Debt0.00-600.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-66.80121.80-86.1037.3045.60-3.30
Net Change in Cash309.1064.40-446.50372.8076.2069.90
Free Cash Flow375.4070.20136.70390.80214.3089.50
Price to Free Cash Flow15.3321.6316.3919.6424.2624.01

Revenue breakdown

Collaboration2024: 24.70M 2025: 26.60M
Product2024: 2.33B 2025: 2.83B
United States2024: 2.36B 2025: 2.86B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.90%5.9M100.0M1.29M
2026-10-156.42%6.4M100.4M1.31M
2026-09-305.83%5.9M100.5M1.25M
2026-09-154.94%5.0M100.5M1.22M
2026-08-315.03%5.1M100.5M1.26M
2026-08-144.53%4.6M100.5M1.26M
2026-07-314.40%4.4M99.9M1.28M
2026-07-155.40%5.3M98.8M1.22M
2026-06-305.60%5.5M98.8M1.23M
2026-06-155.76%5.7M98.7M1.17M
2026-05-295.60%5.5M98.8M1.15M
2026-05-155.22%5.2M98.8M1.15M
2026-04-306.13%6.0M97.8M1.16M
2026-04-155.78%5.6M97.7M1.12M
2026-03-314.67%4.6M97.6M1.14M
2026-03-133.95%3.9M97.6M1.14M
2026-02-273.46%3.4M97.6M1.12M
2026-02-133.24%3.2M97.6M1.10M
2026-01-303.44%3.3M97.1M1.06M
2026-01-153.61%3.5M97.1M1.07M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call65.00107.3111.30.004.1590.000.000.986-0.1800.009
call70.00102.3106.30.003.8750.000.000.985-0.1800.010
call75.0097.40101.30.003.6130.000.000.984-0.1790.011
call80.0092.4096.300.003.3680.000.000.983-0.1780.011
call85.0087.4091.300.003.1380.000.000.982-0.1770.012
call90.0082.4086.300.002.9210.000.000.980-0.1750.013
call95.0077.4081.300.002.7170.000.000.979-0.1740.014
call10072.4076.3067.302.5220.000.000.977-0.1720.015
call10567.4071.3044.952.3360.000.000.975-0.1700.016
call11062.4066.3028.252.1592.000.000.973-0.1680.017
call11557.4061.3052.951.98821.000.000.971-0.1660.018
call12052.4056.3026.901.8243000.000.968-0.1630.019
call12547.4051.3019.831.66511.000.000.965-0.1600.021
call13042.4046.3035.231.5103010.000.962-0.1570.023
call13537.4041.4032.701.38231.000.000.909-0.3530.045
call14032.4036.4018.401.23386.000.000.899-0.3400.048
call14527.5031.4023.181.08736.000.000.887-0.3260.052
call15022.5026.4017.500.9423420.000.872-0.3090.057
call15517.5021.5014.000.81461.000.000.852-0.2900.063
call16012.7014.9012.000.3883822.000.798-0.3240.076
call1658.1012.008.200.5751224.000.738-0.3210.088
call1704.108.104.620.51662.006.000.645-0.3060.101
call1752.004.002.100.34255.005.000.499-0.2680.108
call1800.003.301.300.50937.005.000.369-0.3090.102
call1850.002.500.650.5752.000.000.274-0.3000.090
call1900.002.300.560.69563.000.000.216-0.3120.079
call1950.002.200.400.8142.000.000.192-0.3410.074
call2000.002.150.300.91721.000.000.176-0.3630.070
call2100.002.150.131.09421.000.000.151-0.3920.063
call2200.002.150.551.2802.000.000.137-0.4270.059
call2300.002.150.001.4380.000.000.125-0.4520.056
call2400.002.150.001.5850.000.000.116-0.4720.053
call2500.002.150.901.7211.000.000.109-0.4900.051
call2600.002.150.001.8490.000.000.104-0.5070.049
put65.000.002.150.003.2120.000.00-0.014-0.1710.010
put70.000.002.150.002.9880.000.00-0.015-0.1700.010
put75.000.002.150.002.7790.000.00-0.016-0.1680.011
put80.000.002.150.502.5845.000.00-0.017-0.1670.012
put85.000.002.150.002.4010.000.00-0.019-0.1650.012
put90.000.002.150.002.2290.000.00-0.020-0.1630.013
put95.000.002.150.002.0650.000.00-0.022-0.1610.014
put1000.002.150.001.9090.000.00-0.023-0.1590.015
put1050.002.150.001.7600.000.00-0.025-0.1560.016
put1100.002.150.001.6180.000.00-0.027-0.1540.017
put1150.002.150.701.48111.000.00-0.030-0.1510.018
put1200.002.150.031.3493030.00-0.032-0.1480.020
put1250.002.150.241.2287.000.00-0.035-0.1450.021
put1300.002.200.101.1263180.00-0.038-0.1430.023
put1350.002.200.431.27320.000.00-0.087-0.3050.043
put1400.002.250.471.1331280.00-0.097-0.2930.046
put1450.002.300.350.9861290.00-0.109-0.2770.051
put1500.102.358.800.8473090.00-0.125-0.2610.056
put1550.001.700.550.77628.000.00-0.148-0.2720.063
put1600.002.553.900.7483030.00-0.202-0.3060.076
put1650.002.906.000.62914.000.00-0.262-0.3030.088
put1700.053.507.510.5142.000.00-0.355-0.2870.101
put1751.905.700.000.5070.000.00-0.501-0.2480.108
put1804.908.900.000.5270.000.00-0.633-0.2850.102
put1859.3013.000.000.5850.000.00-0.726-0.2790.090
put19013.8017.800.000.6900.000.00-0.773-0.2980.082
put19518.7022.700.000.7940.000.00-0.802-0.3150.075
put20023.7027.700.000.9010.000.00-0.823-0.3320.071
put21033.7037.700.001.0970.000.00-0.847-0.3680.064
put22043.7047.7044.501.2750.000.00-0.864-0.3960.059
put23053.7057.700.001.4370.000.00-0.875-0.4200.056
put24063.7067.700.001.5880.000.00-0.884-0.4390.053
put25073.7077.700.001.7290.000.00-0.892-0.4570.050
put26083.7087.7080.001.8610.000.00-0.897-0.4720.048

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10144Filing for proposed sale of securities under Rule 144.SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-01SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-11-0210-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-028-KCurrent report2026-11-02SEC
2026-10-30SCHEDULE 13GSEC
2026-10-30144Filing for proposed sale of securities under Rule 144.SEC
2026-10-15SCHEDULE 13G/ASEC
2026-10-073Initial statement of beneficial ownership of securities2026-09-28SEC
2026-09-288-KCurrent report2026-09-25SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-14144Filing for proposed sale of securities under Rule 144.SEC
2026-09-14144Filing for proposed sale of securities under Rule 144.SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-07-318-K/A2026-05-14SEC
2026-07-31S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11002.29M2
2026-100044.70K1
2026-0900826.37K3
2026-080000
2026-07005.42M6
2026-060013.58M6
2026-050043.45M6
2026-040000
2026-030000
2026-020000
2026-01004.83M1
2025-12003.93M4
2025-11005.83M4

Institutional holders

Manager% owned
BlackRock, Inc.13.64%
JPMORGAN CHASE & CO6.36%
DODGE & COX5.55%
VANGUARD PORTFOLIO MANAGEMENT LLC4.95%
VANGUARD CAPITAL MANAGEMENT LLC4.52%
STATE STREET CORP4.36%
AQR CAPITAL MANAGEMENT LLC3.80%
RENAISSANCE TECHNOLOGIES LLC2.32%
GEODE CAPITAL MANAGEMENT, LLC2.09%
TWO SIGMA INVESTMENTS, LP2.06%

Funds

Fund% owned
Dodge & Cox Stock Fund3.94%
iShares Core S&P Mid-Cap ETF3.42%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.18%
VANGUARD SMALL-CAP INDEX FUND2.29%
JPMorgan Growth Advantage Fund1.35%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.32%
VANGUARD EXTENDED MARKET INDEX FUND1.15%
JPMorgan Mid Cap Growth Fund1.11%
State Street SPDR S&P MidCap 400SM ETF Trust0.77%
iShares Biotechnology ETF0.70%

OakChart. NBIX. Cached 15 minutes.